{
  "case_id": "EI02-1152",
  "year": 2002,
  "patient_info": {
    "age_range": "Unknown",
    "gender": "Other"
  },
  "diagnosis": "Immuno Disorders",
  "secondary_conditions": [
    "Antiphospholipid Syndrome"
  ],
  "complications": [],
  "symptoms": [],
  "treatment_category": "Special Proc",
  "treatment_subcategory": "Other",
  "treatments_requested": [
    {
      "name": "Autologous Bone Marrow Transplant",
      "drug_type": null,
      "procedure_type": "other",
      "is_procedure": true,
      "other_or_notes": "Experimental/Investigational"
    }
  ],
  "treatments_tried_but_failed": [],
  "treatments_tried_and_worked": [],
  "treatments_not_tried": [],
  "is_denial_upheld": false,
  "issues_considered": [
    "medical_necessity",
    "plan_coverage"
  ],
  "other_issues": null,
  "guidelines_support": null,
  "guidelines_not_support": null,
  "guidelines_details": null,
  "soc_support": null,
  "soc_not_support": null,
  "soc_details": null,
  "study_support": null,
  "study_details": [],
  "key_questions": [
    "medical_necessity",
    "plan_coverage"
  ],
  "expedited": true,
  "rationale": "Three physician reviewers concluded that autologous bone marrow transplant is likely to be more beneficial for the treatment of the enrollee's catastrophic autophospholipid syndrome/severe systemic lupus than any available standard therapy. The review organization overturned the health plan's denial based on these findings.",
  "reviewer_credentials": "Three physician reviewers with expertise in experimental/investigational treatments."
}